4/15
07:30 am
pstv
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
Low
Report
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
4/9
08:15 am
pstv
Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.
High
Report
Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.
4/9
07:30 am
pstv
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
High
Report
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
4/8
07:30 am
pstv
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Low
Report
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
4/7
07:30 am
pstv
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
Medium
Report
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
4/4
01:04 am
pstv
Medium
Report
4/2
08:09 pm
pstv
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives [Yahoo! Finance]
Medium
Report
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives [Yahoo! Finance]
3/31
05:15 pm
pstv
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/31
04:30 pm
pstv
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
3/31
10:57 am
pstv
Plus Therapeutics (PSTV) had its "hold" rating reaffirmed by D. Boral Capital.
Low
Report
Plus Therapeutics (PSTV) had its "hold" rating reaffirmed by D. Boral Capital.
3/31
08:03 am
pstv
Plus Therapeutics Announces Reverse Stock Split [TheStreet.com]
Low
Report
Plus Therapeutics Announces Reverse Stock Split [TheStreet.com]
3/31
07:30 am
pstv
Plus Therapeutics Announces Reverse Stock Split
High
Report
Plus Therapeutics Announces Reverse Stock Split
3/26
08:20 am
pstv
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors [Yahoo! Finance]
Low
Report
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors [Yahoo! Finance]
3/26
07:30 am
pstv
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
Low
Report
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
3/19
02:52 pm
pstv
Plus Therapeutics (PSTV) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $3.00 price target on the stock.
Low
Report
Plus Therapeutics (PSTV) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $3.00 price target on the stock.
3/19
07:30 am
pstv
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
Low
Report
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
3/12
04:23 pm
pstv
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout [Yahoo! Finance]
High
Report
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout [Yahoo! Finance]
3/12
04:15 pm
pstv
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
High
Report
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
2/25
08:03 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ [Yahoo! Finance]
2/25
07:30 am
pstv
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
Medium
Report
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
2/6
07:12 pm
pstv
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
Low
Report
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
2/3
09:00 am
pstv
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
Low
Report
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
1/23
07:09 am
pstv
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/22
11:40 am
pstv
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
Low
Report
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
1/22
10:45 am
pstv
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]
Low
Report
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]